Descriptive pharmacoepidemiological study on the use of Symbicort Turbuhaler in the treatment of asthma in France and impact of a new therapeutic strategy on the compliance and control of asthma

Inclusion Criteria:

• Asthmatic patients treated for this disease with Symbicort Turbuhaler
• Patients monitored for asthma by the doctor for at least 12 months
• Patients seen in outpatient care at the baseline visit
• Patients agreeing to participate in the study

Exclusion Criteria:

• Patients with any chronic lower respiratory disease other than asthma
• Patients receiving anti-IgE agents in the last 4 months
• Patients receiving desensitisation treatment outside of the maintenance phase
• Patients deemed to be unable to respond to the study for linguistic or cognitive reasons

Community sample